Brain scans for Alzheimer's could be widespread soon
Wednesday 08 June 2011
A brain scan to detect Alzheimer's disease could be available in hospitals worldwide within the next year and could boost efforts to detect the degenerative and fatal condition, experts said on Monday.
The technique, known as a positron emission tomography (PET) scan, can find and analyze a protein known as beta-amyloid, which is linked to Alzheimer's.
"Amyloid imaging with PET scans is expected to be widely available soon for clinical practice," said Christopher Rowe, a professor of nuclear medicine at Austin Hospital, Victoria, Australia.
"It will be an important new tool in the assessment of cognitive decline."
The results from three studies on advances in PET scans for Alzheimer's were presented at a meeting of the Society for Nuclear Medicine's annual meeting in San Antonio, Texas.
Researchers said that the new methods will be of growing importance as the world population ages, and could provide clues toward treating Alzheimer's. There is no known cure.
About 18 million people worldwide suffer from Alzheimer's, the most common form of dementia.
"From a macro perspective, amyloid imaging with PET scans can help to ascertain the likelihood that individuals will deteriorate cognitively within a few years, thereby enabling more efficient channeling of health care resources," said Kevin Ong, a research scientist at Austin Hospital, Melbourne, Australia.
"From a micro perspective, planning and lifestyle modifications are possible for individuals who seek screening for Alzheimer's disease."
Such scans could find clues of the onset of Alzheimer's long before symptoms present. Previous research has shown that the disease can begin as much as decade before signs of dementia appear.
Amyloid plaque is a found in the brains of healthy older people and builds up over time. Larger, faster buildup is linked to quicker memory decline and wasting away of brain tissue.
Amyloid plaques typically grow by about two to three percent per year, and are found in about 12 percent of people in their 60s, 30 percent of those in their 70s and 55 percent of people over age 80, the researchers said.
The studies presented spanned several years of research and involved hundreds of patients at all stages of cognitive function.
Two of the studies suggested that imaging agents known as F-18 labeled tracers, F-18 Florbetaben and F-18 Florbetapir, are the most likely to move into clinical practice in the near term.
The Sistine Chapel is set to be illuminated with thousands of LEDs
Gillian Anderson lays into gender disparity in Hollywood
Life & Style blogs
An app for the amorous: Could Good2Go end disputes about sexual consent - without being a passion-killer?
The Fappening: After the third wave of leaked celebrity photos, why can't we stop it?
Stoptober: How I stopped smoking for good
Wild ram head-butts drone out the sky, waits for pilot to turn up then head-butts him too
Olive oil could help to reverse heart failure, scientists claim
- 1 Snoop Dogg and Jared Leto buy a stake in Reddit as A-list invests $50m
- 2 Prince held a Facebook Q&A and this is the only question he answered...
- 3 'F*ck it, I quit': KTVA reporter Charlo Greene quits live on air in spectacular fashion
- 4 35,000 walrus gather on north-west Alaska beach 'for a rest'
- 5 A teacher speaks out: 'I'm effectively being forced out of a career that I wanted to love'
- < Previous
- Next >
£400 - £450 Per Day: Clearwater People Solutions Ltd: My client are looking fo...
£40000 - £45000 Per Annum + benefits: Clearwater People Solutions Ltd: Domino ...
£35000 - £45000 per annum + benefits: Ashdown Group: A highly successful, inte...
£36000 - £37000 per annum: Randstad Education Group: Experienced SEN Teacher n...